Solvemed Group is a VC-backed Neuroscience AI company working to redefine patient care and drug discovery. Our founders experienced first-
hand the grave consequences of poor diagnostic standards in neurodegenerative diseases. With the primary focus in Parkinson’s disease, we leverage our proprietary machine learning technology to develop novel diagnostic-predictive digital biomarkers to enable first-in-class, accurate, early and cost-effective diagnostic and monitoring tools. We also revolutionise drug discovery as our biomarkers enable disease-modifying neurological drugs. We work to enable better care and improved treatment outcomes for neurology patients. Our work has the potential to benefit healthcare systems by optimising diagnostic pathways and reducing the financial burden imposed by inadequate diagnostics. Through our proprietary medical data repositories and innovative analytics, we help our biopharmaceutical industry partners drive clinical trial efficiency and make first-in-class disease-modifying drugs possible. Everything we do is strongly embedded in world-class science. Our global team of renowned scientists and technology experts works closely with clinical researchers from top research institutions, such as Oxford University, University College London, and Harvard Medical School, among other.